Physician profile
Veronica E Bartlett
NPI 1003111576
$5,146.86
in general payments reported to CMS, 2019-2025
24 companies · $195 in 2025
The $195 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $977 · 2022: $1,341 · 2023: $1,110 · 2024: $1,524 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,829.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,179.37 | 2021-2025 | Farxiga, Airsupra |
| Amgen INC. | $857.43 | 2021-2025 | Repatha, Krystexxa, Evenity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $618.89 | 2022-2024 | Caplyta |
| Abbvie INC. | $451.43 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $388.24 | 2022 | |
| Astellas Pharma US INC | $266.01 | 2024 | Veozah |
| Lilly USA, LLC | $260.05 | 2021-2024 | Jardiance |
| W. L. Gore & Associates, INC. | $159.09 | 2024 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| Otsuka America Pharmaceutical, INC. | $133.53 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $131.27 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $124.45 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $123.75 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $92.77 | 2021 | |
| Novo Nordisk INC | $82.93 | 2021-2023 | Rybelsus, Ozempic |
| Horizon Therapeutics Plc | $52.29 | 2022-2023 | Krystexxa |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uswm, LLC | $51.51 | 2021 | |
| Hologic Sales and Service, LLC | $34.79 | 2021-2022 | |
| Pfizer INC. | $34.60 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $19.58 | 2022 | |
| Dexcom, INC. | $18.53 | 2024 | Dexcom G6 Transmitter |
| Ultragenyx Pharmaceutical INC. | $17.43 | 2021 | |
| Gilead Sciences, INC. | $17.40 | 2022 | |
| Glaxosmithkline, LLC. | $17.19 | 2024 | Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $14.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Bartlett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.